<DOC DOCNO="nw/xinhua/00/chtb_0057@0057@xinhua@nw@en@on">
<ENAMEX TYPE="ORG">Xinhua News Agency</ENAMEX> , <ENAMEX TYPE="GPE">Beijing</ENAMEX> , <ENAMEX TYPE="DATE">December 18</ENAMEX> , by wire
<ENAMEX TYPE="DATE">Today</ENAMEX> researchers from <ENAMEX TYPE="GPE">China</ENAMEX> 's <ENAMEX TYPE="ORG">Institute of Traditional Chinese Medicine</ENAMEX> announced that they had , using herbal medicine , successfully extracted a new kind of medicine " Tang Maikang " with special curative effects for diabetes .
Concerned experts believed that successful developments and marketing of this new medicine would help prevent the spread of Diabetes II in such developing countries as <ENAMEX TYPE="GPE">China</ENAMEX> , <ENAMEX TYPE="GPE">India</ENAMEX> and <ENAMEX TYPE="GPE">Africa</ENAMEX> , etc .
At <ENAMEX TYPE="EVENT">the " Diabetes Prevention and Countermeasure Symposium "</ENAMEX> held by <ENAMEX TYPE="ORG">the Chinese Research Institute of Chinese Medicine</ENAMEX> and attended by academicians , medical experts and biologists from <ENAMEX TYPE="ORG">the Chinese Academy of Sciences</ENAMEX> , <ENAMEX TYPE="ORG">the Chinese Academy of Medical Sciences</ENAMEX> , etc. , reporters learn that at present there are <ENAMEX TYPE="CARDINAL">more than 130 million</ENAMEX> diabetics in the world and <ENAMEX TYPE="PERCENT">90 %</ENAMEX> of them suffer from Diabetes II .
The complications of Diabetes II , such as coronary heart disease , cerebrovascular disease , nephropathy , blindness and lower extremities necrosis , etc. , have become the mankind 's <ENAMEX TYPE="ORDINAL">third</ENAMEX> biggest killer next to cancer and AIDS .
At present , there are <ENAMEX TYPE="CARDINAL">more than 20 million</ENAMEX> diabetics in <ENAMEX TYPE="GPE">China</ENAMEX> which , after the <ENAMEX TYPE="GPE">US</ENAMEX> , is <ENAMEX TYPE="ORDINAL">second</ENAMEX> highest in the world .
Experts predict that , with the development of the economy , the improvement of living standards and dietary habits , in <ENAMEX TYPE="DATE">the 21st century</ENAMEX> , Diabetes II would prevail in such developing countries as <ENAMEX TYPE="GPE">China</ENAMEX> , <ENAMEX TYPE="GPE">India</ENAMEX> , <ENAMEX TYPE="GPE">Africa</ENAMEX> , etc .
In <ENAMEX TYPE="DATE">recent years</ENAMEX> , the annual medical expenses for diabetes in <ENAMEX TYPE="GPE">U.S.</ENAMEX> are about <ENAMEX TYPE="MONEY">10 billion US dollars</ENAMEX> and <ENAMEX TYPE="GPE">India</ENAMEX> 's diabetes medical expenses <ENAMEX TYPE="DATE">last year</ENAMEX> were <ENAMEX TYPE="MONEY">610 million US dollars</ENAMEX> .
There are no specific statistics on it in <ENAMEX TYPE="GPE">China</ENAMEX> , but the number of <ENAMEX TYPE="NORP">Chinese</ENAMEX> diabetics is increasing by <ENAMEX TYPE="CARDINAL">750,000</ENAMEX> annually .
Researchers presented , saying that none of the various chemosynthetic , sugar - lowering drugs currently commonly used outside the country have a very great preventive effect against the complications of diabetes .
" Tang Maikang " granules are able to reduce not only blood sugar , but also cholesterol and triglycerides remarkably , and has special curative effects on the complications of diabetes .
<ENAMEX TYPE="ORG">The Ministry of Public Health</ENAMEX> has issued a document specifying it as a confidential variety of new national medicine .
An academician of <ENAMEX TYPE="ORG">the Chinese Academy of Science</ENAMEX> and traditional medicine consultant to the <ENAMEX TYPE="ORG">WHO</ENAMEX> , <ENAMEX TYPE="PERSON">Keji Chen</ENAMEX> , etc. and expert professors attending the seminar believe that the birth of " Tang Maikang " is a good thing , and at the same time hope the researchers make further observations on insulin and changes in blood flow and perform in - depth research on the effective content and mechanism of " Tang Maikang " to ensure its invincible position in the world and in competition with the developed countries .
To improve the competitiveness on the international market of such new <ENAMEX TYPE="NORP">Chinese</ENAMEX> medicine as " Tang Maikang " that are geared to <ENAMEX TYPE="DATE">the 21st century</ENAMEX> , <ENAMEX TYPE="ORG">Zhonghui Pharmaceutical Factory</ENAMEX> of <ENAMEX TYPE="GPE">China</ENAMEX> 's <ENAMEX TYPE="ORG">Chinese Medicine Research Institute</ENAMEX> invested <ENAMEX TYPE="MONEY">200 million yuan</ENAMEX> and to build a production base with an annual production capacity of <ENAMEX TYPE="MONEY">5 billion yuan</ENAMEX> in <ENAMEX TYPE="GPE">Chengdu , Sichuan</ENAMEX> .
It is estimated that the production value of " Tang Maikang " will reach <ENAMEX TYPE="MONEY">600 million yuan</ENAMEX> next year and <ENAMEX TYPE="MONEY">1.5 billion yuan</ENAMEX> in <ENAMEX TYPE="DATE">2000</ENAMEX> .
According to investigations , the annual global sale of herbal medicine is about <ENAMEX TYPE="MONEY">15 billion US dollars</ENAMEX> , but <ENAMEX TYPE="GPE">China</ENAMEX> 's export of <ENAMEX TYPE="NORP">Chinese</ENAMEX> medicine is only <ENAMEX TYPE="MONEY">600 million US dollars</ENAMEX> , and <ENAMEX TYPE="PERCENT">70 %</ENAMEX> of the medicinal materials are have no added value .
Experts from medicine circles predict that the marketing of " Tang Maikang " and the completion of the production base will help to change the slump of nationally made <ENAMEX TYPE="NORP">Chinese</ENAMEX> medicine in the international market of <ENAMEX TYPE="NORP">Chinese</ENAMEX> medicine .
-LRB- End -RRB-
</DOC>
